Human Fc gamma RIIIA / CD16a (F176) Protein, His Tag (SPR & BLI verified) (CAT#: FC-P046-ZP) Datasheet

Product Type
Protein
Description
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.7 kDa. The protein migrates as 39-51 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Species
Human
Construction
It contains AA Gly 17 - Gln 208 (Accession # P08637-1).
Expression
HEK293
N-Terminal
Predicted N-terminus: Gly 17
Tag
His Tag
Endotoxin
Less than 1.0 EU per μg by the LAL method.
Purity
>95% as determined by SDS-PAGE.
Buffer
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Target
Fc gamma RIIIA / CD16a
Background
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16B is also kown as FCGR3B and FCG3B, is expressed specifically by polymorphonuclear leukocytes (neutrophils) and stimulated eosinophils. CD16B is the low affinity receptor for the Fc region of immunoglobulins gamma. FCGR3B binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, FCG3B is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. CD16B may serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.
Alternative Names
FCGR3A, CD16A, FCG3, FCGR3, IGFR3

Figure 1 Molecular Characterization

Figure 2 SDS-PAGE

Figure 3 Bioactivity-SPR

Figure 4 Bioactivity-BLI

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK